WS
PRTK

Wedbush Securities’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Wedbush Securities’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-45,369
Closed -$245K – 1011
2020
Q3 		$245K Buy
45,369
+3,852
+9% +$19.1K 0.02% 703
2020
Q2 		$217K Buy
41,517
+1,425
+4% +$6.33K 0.02% 744
2020
Q1 		$126K Buy
40,092
+4,046
+11% +$14.9K 0.02% 757
2019
Q4 		$145K Sell
36,046
-413
-1% -$1.43K 0.01% 901
2019
Q3 		$158K Sell
36,459
-8,818
-19% -$35.3K 0.02% 859
2019
Q2 		$181K Sell
45,277
-31,053
-41% -$148K 0.02% 846
2019
Q1 		$409K Sell
76,330
-9,161
-11% -$59.2K 0.04% 483
2018
Q4 		$439K Sell
85,491
-13,443
-14% -$102K 0.06% 399
2018
Q3 		$960K Buy
98,934
+72,884
+280% +$735K 0.11% 214
2018
Q2 		$266K Buy
26,050
+15,000
+136% +$170K 0.03% 600
2018
Q1 		$144K Buy
+11,050
New +$165K 0.02% 728

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wedbush Securities's PRTK Position: Q4 2020 in Review

Wedbush Securities sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2020, closing a stake of 45,369 shares — an estimated $245K sold.

Wedbush Securities first reported a position in PRTK in Q1 2018 and held it in 11 quarters. The position peaked at $960K in Q3 2018. 108 funds tracked by Wall St. Rank hold PRTK as of Q4 2020.

  • Wedbush Securities reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Wedbush Securities sold 45,369 Paratek Pharmaceuticals, Inc. shares in Q4 2020, an estimated $245K.
  • Wedbush Securities first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2018 and held it in 11 quarters.
  • Wedbush Securities's Paratek Pharmaceuticals, Inc. position peaked at $960K in Q3 2018.
  • 108 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2020.

Based on Wedbush Securities's 13F filing for Q4 2020, filed 16 Feb 2021.